

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/S.G./	A01	U.S. 6,921,825	07/26/2005	Baraldi et al.	544	251	04/26/2002
	A02						
	A03						
	A04						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01						<input type="checkbox"/>	<input type="checkbox"/>
	B02						<input type="checkbox"/>	<input type="checkbox"/>
	B03						<input type="checkbox"/>	<input type="checkbox"/>
	B04						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/S.G./	C01	Baraldi et al., "Pyrozolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A <sub>3</sub> Adenosine Receptor Antagonists: Influence of the Chain at the N <sup>8</sup> Pyrazole Nitrogen", <i>Journal of Medicinal Chemistry</i> 2000, 43, 4768-4780.
/S.G./	C02	Baraldi et al., "Synthesis, Biological Activity, and Molecular Modeling Investigation of New Pyrozolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Human A <sub>3</sub> Adenosine Receptor Antagonists", <i>Journal of Medicinal Chemistry</i> 2002, 45, 770-780.
	C03	
	C04	
	C05	
	C09	
	C10	
	C11	

EXAMINER

/Shirley Gembeh/

DATE CONSIDERED

11/20/2007

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.